This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Consolidated September 2026 quarter: revenue Rs 2,603 crore, up 36% year on year; net profit up 81%
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 9.8 pts more than Nifty Microcap 250 and 11.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated quarter ended Sep 2026: revenue from operations rose 36.3% year on year to Rs 2,603.48 crore from Rs 1,910.15 crore; profit after tax rose 81.5% to Rs 335.17 crore from Rs 184.71 crore. EBITDA margin expanded 5.19 percentage points to 22.21% from 17.02%. Half year ended Sep 2026 consolidated: revenue Rs 4,753.25 crore, PAT Rs 508.23 crore. Standalone Q2: revenue Rs 2,391.65 crore, PAT Rs 409.36 crore. Review unqualified.
Strong revenue, profit and margin growth may support the share price, although the market reaction will depend on expectations.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹2,603 Cr | ₹1,910 Cr | +36.3% |
| Operating profit | ₹424.2 Cr | ₹215.4 Cr | +96.9% |
| Profit after tax | ₹333.9 Cr | ₹183.7 Cr | +81.8% |
| EBITDA margin | 21.6% | 16.5% | +5.1 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.